RIP kinase Inhibitor

RIP kinase Inhibitors (103):

Cat. No.	Product Name	Effect	Purity

HY-15760

Necrostatin-1	Inhibitor	99.89%
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC₅₀ of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC₅₀=182 nM). Necrostatin-1 is also an IDO inhibitor.

HY-101872

GSK-872	Inhibitor	99.91%
GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.

HY-14622A

Necrostatin 2 racemate	Inhibitor	99.65%
Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect.

HY-100339

GSK583	Inhibitor	98.74%
GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC₅₀ of 5 nM. GSK583 inhibits both TNF-α and IL-6 production with an IC₅₀ value of 200 nM.

HY-158312

UH15-38	Inhibitor	99.80%
UH15-38 is a potent RIPK3 inhibitor with an IC₅₀ value of 20 nM. UH15-38 blocks IAV (influenza A virus)-activated necroptosis. UH15-38 dampens IAV-induced lung injury.

HY-169107

RIPK1-IN-25	Inhibitor
RIPK1-IN-25 (WL8) is a blood-brain permeable RIPK1 inhibitor with EC₅₀ and K_d values are 19.9 and 25 nM, respectively. RIPK1-IN-25 can be used in the study of neurometabolic diseases.

HY-168024

NOD1/2-IN-1	Inhibitor
NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC₅₀ value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC₅₀ values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis.

HY-101872A

GSK-872 hydrochloride	Inhibitor	99.21%
GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 1.8 nM, and inhibits kinase activity with an IC₅₀ of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.

HY-101760

GSK2982772	Inhibitor	99.79%
GSK2982772 is a potent, orally active and ATP competitive RIP1 kinase inhibitor with IC₅₀ values of 16 nM and 20 nM for human and monkey RIP1, respectively.

HY-104021

GSK840	Inhibitor	98.01%
GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 0.9 nM, and inhibits kinase activity with an IC₅₀ of 0.3 nM.

HY-125402

GSK-843	Inhibitor	99.18%
GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC₅₀ of 8.6 nM, and inhibits kinase activity with an IC₅₀ of 6.5 nM. GSK-843 can be used for the research of inflammation.

HY-134050

Apostatin-1	Inhibitor	99.24%
Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (K_D=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of RIPK1 and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin.

HY-18937

WEHI-345	Inhibitor	99.31%
WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation.

HY-112038A

GSK2983559	Inhibitor	98.82%
GSK2983559 is an orally active and potent receptor interacting protein 2 (RIP2) kinase inhibitor. GSK2983559 blocks many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.

HY-114492

GSK547	Inhibitor	99.86%
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.

HY-101032

RIPA-56	Inhibitor	99.94%
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC₅₀ of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.

HY-14622

Necrostatin 2	Inhibitor	99.92%
Necrostatin 2 is a potent necroptosis inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.

HY-138779

ICCB-19 hydrochloride	Inhibitor	99.24%
ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins.

HY-111866

PROTAC RIPK degrader-2	Inhibitor	99.48%
PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes.

HY-103028A

GSK963	Inhibitor	98.24%
GSK963 is a chiral, highly potent and selective inhibitor of RIP1 kinase, with an IC₅₀ of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro.

Name
Email *

	Sorry, but the email address you supplied was invalid.